ArticleJAC-antimicrobial resistance2026
Covalent inhibition of New Delhi metallo-β-lactamases NDM-1 and NDM-5 by 3-bromopyruvate.
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Resistance to β-lactam antibiotics, including carbapenems, mediated by metallo-β-lactamases (MBLs), including the New Delhi metallo-β-lactamase (NDM) family, is increasing. No MBL inhibitors are currently approved for clinical use, with most reported MBL inhibitors acting as metal ion chelators at either the Zn(II) ion active site and/or in solution. The hexokinase inhibitor 3-bromopyruvate (3-BP) has been reported to inhibit NDM-1. This study investigates the ability of 3-BP to restore carbapenem activity against NDM-producing bacterial strains. Materials and methods: The ability of 3-BP to restore meropenem activity was assessed against carbapenem-resistant Results and conclusions: 3-BP selectively restored the antimicrobial activity of meropenem against resistant strains containing genes encoding NDM-1 or NDM-5 but did not restore the antimicrobial activity of amoxicillin against resistant strains containing genes encoding serine β-lactamases. Mass spectrometry studies with NDM-1 and NDM-5 support a mechanism involving covalent reaction of 3-BP with an active site cysteine residue. These results will promote work on the development of covalently reacting MBL inhibitors, a strategy that has been successful for inhibition of the nucleophilic serine β-lactamases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.